neratinib maleate (nerlynx) Report issue

Small molecule Approved FDA
Drugs@FDA

Active Ingredient History

NOW
  • Now
Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer.   Wikipedia

Chemistry

  • SMILES: CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C.O=C(O)/C=C\C(=O)O
  • InChIKey: VXZCUHNJXSIJIM-MEBGWEOYSA-N
  • Mol. Mass: 673.13
  • ALogP: 5.93
  • ChEMBL Molecule:
    neratinib maleate  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$44.4108 - $65.8861
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

neratinib maleate

Organizations (28)

Research & Development (26)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Breast Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Stomach Neoplasms (Phase 1)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial Organizations: 26

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue